Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher-Paul Milne

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|February 8, 2013
PharmacoEconomics. ForewordChristopher-Paul Milne
Food and Drug Law Journal|April 25, 2003
Exploring the frontiers of law and science: FDAMA's pediatric studies incentiveChristopher-Paul Milne
Personalized Medicine|May 23, 2018
Can translational medicine bring us out of the R&D wilderness?Christopher-Paul Milne
Clinical Therapeutics|February 6, 2017
More Efficient Compliance with European Medicines Agency and Food and Drug Administration Regulations for Pediatric Oncology Drug Development: Problems and SolutionsChristopher-Paul Milne
Expert Opinion on Drug Discovery|March 20, 2013
US and European regulatory initiatives to improve R&D performanceChristopher-Paul Milne
Nature Biotechnology|July 31, 2002
Orphan products--pain relief for clinical development headachesChristopher-Paul Milne
Personalized Medicine|May 26, 2018
Biopharmaceutical industry perspectives on the business prospects for personalized medicineChristopher-Paul Milne, Rachael Zuckerman
Food and Drug Law Journal|February 11, 2014
FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?Andrew Wilson, Christopher-Paul Milne
Nature Reviews. Drug Discovery|March 2, 2012
Market watch: industry perspectives on personalized medicineRachael Zuckerman, Christopher-Paul Milne
Clinical Therapeutics|February 18, 2014
The pediatric studies initiative: after 15 years have we reached the limits of the law?Christopher-Paul Milne, Jonathan Davis
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|February 8, 2013
PharmacoEconomics. ForewordChristopher-Paul Milne
Food and Drug Law Journal|April 25, 2003
Exploring the frontiers of law and science: FDAMA's pediatric studies incentiveChristopher-Paul Milne
Personalized Medicine|May 23, 2018
Can translational medicine bring us out of the R&D wilderness?Christopher-Paul Milne
Clinical Therapeutics|February 6, 2017
More Efficient Compliance with European Medicines Agency and Food and Drug Administration Regulations for Pediatric Oncology Drug Development: Problems and SolutionsChristopher-Paul Milne
Expert Opinion on Drug Discovery|March 20, 2013
US and European regulatory initiatives to improve R&D performanceChristopher-Paul Milne
Nature Biotechnology|July 31, 2002
Orphan products--pain relief for clinical development headachesChristopher-Paul Milne
Personalized Medicine|May 26, 2018
Biopharmaceutical industry perspectives on the business prospects for personalized medicineChristopher-Paul Milne, Rachael Zuckerman
Food and Drug Law Journal|February 11, 2014
FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?Andrew Wilson, Christopher-Paul Milne
Nature Reviews. Drug Discovery|March 2, 2012
Market watch: industry perspectives on personalized medicineRachael Zuckerman, Christopher-Paul Milne
Clinical Therapeutics|February 18, 2014
The pediatric studies initiative: after 15 years have we reached the limits of the law?Christopher-Paul Milne, Jonathan Davis
Pageof 3